Mental Health Disparities in South and East Asia: Research Priorities and Collaborative Strategies

By Charmi Patel

July 2, 2024

Introduction

Mental health disparities in South and East Asia present a significant challenge, with high levels of unmet needs. According to global estimates, the WHO(World Health Organization)South-East Asia Region alone accounts for a substantial portion of depression and anxiety cases. In India, the National Mental Health Survey highlighted a concerning 85% treatment gap for depression. Similarly, Nepal’s first national mental health survey revealed significant prevalence rates, emphasising the urgent need for action in these regions.

Research Priorities in South and East Asia

  1. Integrating Mental Health in Perinatal Care(PMH): PMH impacts parents and influences offspring long-term. The WHO stresses integrating mental health screening and treatment in routine perinatal care, especially in low and middle-income countries (LMIC). In LMICs, postnatal depression exceeds 25%, with maternal suicide remaining a leading cause of death at nearly 10%. PMH requires special focus in LMICs, especially where high rates of gender-based violence and intersecting psychological issues exist. The WHO stresses integrating mental health screening and treatment in routine perinatal care, especially in low- and middle-income countries.
  2. Supporting Carers of Individuals with Disabilities: Carers play a vital role in supporting individuals with disabilities but often face neglect and high rates of physical and mental health issues. Research in LMICs, including countries in South and East Asia, highlights the urgent need for tailored support strategies for this overlooked group. For instance, in India, most carers face a lack of adequate support. In Nepal, many carers experience strained family relationships, marital difficulties, and a lower quality of life. In Pakistan, carers often suffer from depression and stigma related to their caregiving roles. A Thai longitudinal study found high psychological distress in carers, influenced by Buddhist family support beliefs, without detailing specifics. A study in Pakistan found carers of psychosis patients often attribute the illness to spiritual and social factors. This belief system, along with associated shame and stigma, affects their help-seeking behaviors and preference for non-medical interventions. The International Mental Health Development Group’s (IMHDG) meeting proposed documenting carers’ experiences, defining support needs, and training professionals, led by carers, clinicians, and researchers.
  3. Utilizing Digital Health Technologies (DHT): DHTs leverage the widespread availability of personal devices to address barriers to accessing care and training, particularly in regions where mobile device ownership and internet usage are high, but face-to-face services are limited. In the Asia-Pacific region, 75% use smartphones and 45% use mobile internet, according to a 2022 report. A survey of 192 early-career psychiatrists, junior doctors, and medical students from India, Nepal, Indonesia, Thailand, Pakistan, and Japan revealed that 77% believe DHTs can be as effective and useful as face-to-face care, although most respondents lacked formal training in their use. IMHDG calls for studies on DHT use, care models, and privacy issues in mental health, involving lived experience.
  4. Building Research Capacity: To grow research efforts, develop culturally-validated screening tools for mental disorders, guided by local experts and community insights. Introducing research staff and routine data collection can track outcomes and diversify regional research output. This approach is particularly useful for exploring community carer health. A positive step is the 2022 Paro Declaration, committing WHO South-East Asia members to enhance local mental health research.

Conclusion

The IMHDG’s research priorities and collaborative strategies are crucial for addressing mental health needs in South and East Asia.The IMHDG identified four priority areas, outlined evidence, gaps, and collaboration opportunities within and beyond the region. These areas are interconnected and reflect a range of intersecting challenges. Focusing on key research areas and fostering collaboration can significantly enhance mental health outcomes and inspire global change.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.